Ascendis Pharma
ASND
Ascendis Pharma (ASND) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $3.23
- EPS estimate
- $1.74
- EPS surprise
- +85.97%
- Revenue surprise
- +2.54%
- Revenue
- $387.5M
- Revenue estimate
- $377.9M
- Reported
- Aug 13, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | $1.74 | $3.23 | +85.97% | $387.5M | SEC |
| Q1 2026 | May 7, 2026 | $0.21 | $11.26 | +5241.35% | $284.9M | SEC |
| Q4 2025 | Feb 11, 2026 | −$0.22 | −$0.65 | −187.62% | $290.7M | SEC |
| Q3 2025 | Nov 12, 2025 | −$0.29 | −$1.17 | −309.56% | $250.7M | SEC |
| Q2 2025 | Aug 7, 2025 | −$1.51 | −$0.97 | +36.23% | $186.2M | SEC |
| Q1 2025 | May 1, 2025 | −$1.59 | −$1.71 | −7.68% | $109.2M | SEC |
| Q4 2024 | Feb 12, 2025 | −$1.02 | −$0.66 | +35.00% | $180.0M | SEC |
| Q3 2024 | Nov 14, 2024 | −$1.74 | −$1.92 | −9.92% | $64.4M | SEC |
| Q2 2024 | Sep 3, 2024 | −$1.56 | −$2.05 | −30.96% | $38.6M | SEC |
| Q1 2024 | May 2, 2024 | −$1.59 | −$2.48 | −55.73% | $103.5M | SEC |
| Q4 2023 | Feb 7, 2024 | −$2.00 | −$1.70 | +15.13% | $152.0M | SEC |
| Q3 2023 | Nov 7, 2023 | −$2.51 | −$2.84 | −13.37% | $47.4M | SEC |
| Q2 2023 | Sep 5, 2023 | −$2.75 | −$2.36 | +14.38% | $51.7M | SEC |
| Q1 2023 | Apr 27, 2023 | −$2.88 | −$2.15 | +25.50% | $36.4M | SEC |
| Q4 2022 | Feb 16, 2023 | −$2.84 | −$3.96 | −39.64% | $24.1M | SEC |
| Q3 2022 | Nov 2, 2022 | −$2.49 | −$3.04 | −22.10% | $15.4M | — |
| Q2 2022 | Aug 10, 2022 | −$2.27 | −$1.53 | +32.52% | $6.5M | — |
| Q1 2022 | May 11, 2022 | −$2.28 | −$2.45 | −7.39% | $7.6M | — |
| Q4 2021 | Mar 2, 2022 | −$2.62 | −$2.11 | +19.24% | $5.6M | — |
| Q3 2021 | Nov 10, 2021 | −$2.67 | −$1.70 | +36.26% | $1.3M | — |
Quarterly revenue
Frequently asked questions
When did Ascendis Pharma (ASND) last report earnings?
Ascendis Pharma last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did ASND beat earnings estimates?
Yes. Ascendis Pharma reported EPS of $3.23 for Q2 2026 against a $1.74 estimate — a 85.97% beat.
How much revenue did ASND report last quarter?
Ascendis Pharma reported $387.5M in revenue for Q2 2026, against a consensus estimate of $377.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.